Post-transplant diabetes mellitus. The role of immunosuppression

Drug Safety

Volumn 16, Issue 4, 1997, Pages 242-257

  Jindal, Rahul M ^a,b   Sidner, Richard A ^a   Milgrom, Martin L ^a  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; BREQUINAR; CORTICOSTEROID; CYCLOSPORIN; GLUCOSE; HEMOGLOBIN A1C; IMMUNOSUPPRESSIVE AGENT; INSULIN; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CUSHING SYNDROME; DEATH; DIABETES MELLITUS; DIABETOGENESIS; DYSLIPIDEMIA; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY GRAFT; LEUKOPENIA; LIVER TRANSPLANTATION; METABOLIC DISORDER; NONHUMAN; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PANCREAS ISLET BETA CELL; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RISK; STROKE;

EID: 0030896309     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199716040-00002     Document Type: Article

References (126)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in IDDM. N Engl J Med 1993; 329: 977-86
2. American Diabetes Association. Position statement: implications of the Diabetes Control and Complications Trial. Clin Diabetes 1993; 11: 91-6
3. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes 1996; 45: 1289-98
4. Gerstein H, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996; 347: 949-50
5. Jindal RM, Emre S, Meneses P, et al. Diabetogenicity of FK506 versus CyA in liver transplant recipients [abstract]. Hepatology 1993; 18: 745A
6. Jindal RM, Popsecu I, Schwartz ME, et al. Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. Transplantation 1994; 58: 370-2
7. Jindal RM. Posttransplant diabetes mellitus - a review. Transplantation 1994; 58: 1289-98
8. Steinmuller TM, Graf K-J, Schleicher J, et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism - a randomized trial. Transplantation 1994; 58: 669-74
9. Peters AL, Davidson MB, Schriger DL, et al., for the Meta-Analysis Research Group on the Diagnosis of Diabetes using Glycated Hemoglobin Levels. An analysis using glycosylated hemoglobin levels. JAMA 1996; 276: 1246-52
10. Krausz Y, Wollheim CB, Siegal E, et al. Possible role for calmodulin in insulin release: studies with trifluperazine in the rat pancreatic islets. J Clin Invest 1980; 66: 603-7
11. Davis M. Immunosuppressive drugs. In: Neuberger J, Lucey MR, editors. Liver transplantation: practice and management. London: British Medical Association 1994: 190-209
12. Hirano Y, Hisatomi A, Ohara K, et al. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. Transplantation 1992; 54: 883-7
13. Henke W, Jung K. Comparison of the effects of the immunosuppressive agents FK506 and cyclosporine A on rat kidney mitochondria. Biochem Pharmacol 1993; 46: 829-32
14. Ueki M, Yasunami Y, Ina K, et al. Diabetogenic effects of FK506 on renal subcapsular islet isografts in rats. Diabetes Res Clin Pract 1993; 20: 11-9
15. Herold KC, Nagamatsu S, Buse JB, et al. Inhibition of glucose-stimulated insulin release from BTC3 cells and rodent islets by an analog of FK506. Transplantation 1993; 55: 186-92
16. Ost L. Effects of cyclosporine on prednisolone metabolism. Lancet 1984; I: 451
17. Jindal RM, Hughes D, Pescovitz MD, et al. Association of HLA antigens with posttransplant diabetes mellitus in recipients of liver transplants [abstract]. Hepatology 1995; 22: 434A
18. David SS, Cheigh JS, Brown Jr DW, et al. HLA-A28 and steroid induced diabetes in renal transplant patients. JAMA 1980; 243: 532-3
19. D'Apice AJF, Mathews JD, Tait BD, et al. Association of HLA antigens with glucose tolerance following renal transplantation. Tissue Antigens 1978; 11: 423-6
20. Rizza MA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab 1982; 54: 131-8
21. Munch A. Glucocorticoid inhibition of glucose uptake by peripheral tissues: old and new evidence, molecular mechanisms and physiological significance. Perspect Biol Med 1971; 14: 265-89
22. Kahn CR, Goldfine ID, Neville DM, et al. Alteration in insulin binding induced by changes in vivo in the levels of glucocorticoids and growth hormone. Endocrinology 1978; 103: 1054-66
23. Venkatesan N, Davidson MB, Huchinson A. Possible role for the glucose-fatty acid cycle in dexamethasone-induced insulin antagonism in rats. Metabolism 1987; 36: 883-91
24. Ekstrand AV, Eriksson JG, Gronhagen-Riska C, et al. Insulin resistance and insulin deficiency in the pathogenesis of posttransplant diabetes in man. Transplantation 1992; 53: 563-9
25. Zimmerman T, Horber F, Roderiguez N, et al. Contribution of insulin resistance to catabolic effect of prednisone on leucine metabolism in humans. Diabetes 1989; 38: 1238-44
26. Hahn HJ, Laube F, Lucke S, et al. Toxic effects of cyclosporine on the endocrine pancreas of Wistar rats. Transplantation 1986; 41: 44-7
27. Hahn HJ, Dunger A, Laube F, et al. Reversibility of the acute effect of cyclosporine A on pancreatic B cells of Wistar rats. Diabetologia 1986; 29: 489-94
28. Andersson A, Borg H, Hallberg A, et al. Long-term effects of cyclosporin A on cultured mouse pancreatic islets. Diabetologia 1984; 27: 66-9
29. Gillison SL, Bartlett ST, Curry DL. Inhibition by cyclosporine of insulin secretion - a beta cell-specific alteration of islet tissue function. Transplantation 1991; 52: 890-5
30. Eun HM, Pak CY, Kim CJ, et al. Role of cyclosporine A in macromolecular synthesis of beta-cells. Diabetes 1987; 36: 952-8
31. Robertson RP. Cyclosporine-induced inhibition of insulin secretion in isolated rat islets and HIT cells. Diabetes 1986; 35: 1016-9
32. Wahlstrom HE, Akimoto R, Endres D, et al. Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of short-term cyclosporine treatment. Transplantation 1992; 53: 1190-5
33. Alejandro R, Feldman E, Bloom AD, et al. Effect of cyclosporine on insulin and C-peptide secretion in healthy beagles. Diabetes 1989; 38: 698-703
34. Stegall MD, Chabot J, Weber C, et al. Pancreatic islet transplantation in cynomolgus monkeys. Transplantation 1989; 48: 944-50
35. Ishizuka J, Gugliuzza KK, Wassmuth Z, et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. Transplantation 1993; 56: 1486-90
36. Schilfgaarde van RV, Burg van der MPM, Suylichem van PTR, et al. Reversible suppression of canine beta cell function by cyclosporine A is dose dependent. Transplant Proc 1986; 18: 1556-7
37. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995; 59: 485-90
38. Tamura K, Fujimura T, Tsutsumi T, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of EK506 binding protein-12 in pancreatic B-cell. Transplantation 1995; 59: 1606-13
39. Hirano Y, Mitamura T, Tamura T, et al. Mechanism of FK506 induced glucose intolerance in rats. J Toxicol Sci 1994; 19: 61-5
40. Hirano Y, Fujihira S, Ohara K, et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 1992; 53: 889-94
41. Tze WJ, Tai J, Murase N, et al. Effect of FK506 on glucose metabolism and insulin secretion in normal rats. Transplant Proc 1991; 23: 3158-60
42. Rilo HLR, Zeng Y, Alejandro R, et al. Effect of FK506 on function of human islets of Langerhans. Transplant Proc 1991; 23: 3164-5
43. Strasser S, Alejandro R, Shapiro TE, et al. Effect of FK506 on insulin secretion in normal dogs. Metabolism 1992; 41: 64-7
44. Collier DStJ, Calne R, Thiru S, et al. FK506 in experimental renal allografts. Transplant Proc 1987; 19: 3975-7
45. Todo S, Demetris A, Uedu Y, et al. Renal transplantation in baboons under FK506. Surgery 1989; 106: 444-51
46. Ericzon B-G, Wijnen RMH, Kubota K, et al. FK506-induced impairment of glucose metabolism in the primate - studies in pancreatic transplant recipients and in nontransplanted animals. Transplantation 1992; 54: 615-20
47. Jindal RM, Tepper MA, Soltys K, et al. Deoxyspergualin - a novel immunosuppressant. Mt Sinai J Med 1994; 61: 51-6
48. Menger MD, Jager S, Walter P, et al. The influence of ± 15-deoxyspergualin on revascularization of xenogeneic transplanted islets of Langerhans. Transplant Proc 1990; 22: 1631-2
49. Strandell E, Anderson A, Groth CG, et al. Effects of 15-deoxyspergualin on pancreatic islet B-cell function in vitro and on the development of diabetes after multiple low dose streptozotocin administration. Pharmacol Toxicol 1989; 65: 114-8
50. Jindal RM, Soltys K, Yost F, et al. Transplantation of pig pancreatic islets to rat using deoxyspergualin monotherapy. Transplant Proc 1994; 26: 1108-9
51. Jindal RM, Soltys K, Yost F, et al. Effect of deoxyspergualin on the endocrine function of the rat pancreas. Transplantation 1993; 56: 1275-7
52. Xenos ES, Casanova D, Sutherland DER, et al. The in vivo and in vitro effect of 15-deoxyspergualin on pancreatic islet function. Transplantation 1993; 56: 144-7
53. Kahan BD, Chang JY, Sehgal S. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991; 52: 185-91
54. Fabian MC, Lakey JRT, Rajotte RV, et al. The efficacy and toxicity of rapamycin in murine islet transplantation. Transplantation 1993; 56: 1137-42
55. Andoh TF, Lindsley J, Franceschini N, et al. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62: 311-6
56. Sharma K, Ziyadeh FN. Hyperglycaemia and diabetic kidney disease: the case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139-46
57. Kneteman NM, Lakey JRT, Wagner T, et al. Beneficial metabolic impact of the novel immunosuppressant rapamycin in chronic canine islet autograft recipients. Transplant Proc 1995; 27: 3213
58. Kneteman NM, Lakey JRT, Wagner T, et al. The metabolic impact of rapamycin (sirolimus) in chronic islet graft function. Transplantation 1996; 61: 1206-10
59. Anderson S, Rennke HG, Garcia DL, et al. Short- and long-term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989; 36: 526-36
60. DiJoseph JF, Sharma RN, Chang JY. The effects of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 1992; 53: 507-13
61. Platz KP, Sollinger HW, Hullet DA, et al. RS-61443 - a new, potent immunosuppressive agent. Transplantation 1991; 51: 27-31
62. Hao L, Lafferty KJ, Allison AC, et al. RS-61443 allows islet allografting and specific tolerance induction in adult mice. Transplant Proc 1990; 22: 876-9
63. Hao L, Calcinaro F, Gill RG, et al. Facilitation of specific tolerance induction in adult mice by RS-61443. Transplantation 1992; 53: 590-5
64. McGeown MG, Douglas JF, Brown WA, et al. Advantages of low dose steroid from the day after renal transplantation. Transplantation 1980; 29: 287-9
65. Hill CM, Rajkumar KV, Douglas JF, et al. Glycosuria and hyperglycaemia after kidney transplantation. Lancet 1974; II: 490-2
66. Lampe EW, Ruiz JO, Simmons RL, et al. Hyperglycaemic non-ketotic coma after renal transplantation. Am J Surg 1974; 127: 342-4
67. Arner P, Gunnarsson R, Blomdahl S, et al. Some characteristics of steroid diabetes: a study in renal transplant recipients receiving high dose corticosteroid therapy. Diabetes Care 1983; 6: 23-5
68. Gunnarsson R, Klintmalm G, Lundgren G, et al. Deterioration in glucose metabolism in pancreatic transplant recipients after conversion from azathioprine to cyclosporine. Transplant Proc 1984; 16: 709-12
69. Tyden G, Brattstrom C, Gunnarsson R, et al. Metabolic control at 2 months to 4.5 years after pancreatic transplantation, with special reference to the role of cyclosporine. Transplant Proc 1987; 19: 2294-6
70. Ried M, Gibbons S, Kwok D, et al. Cyclosporine levels in human tissues of patients treated for one week to one year. Transplant Proc 1983; 15: 2434-7
71. Friedman EA, Shyh TP, Beyer MM, et al. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985; 5: 196-202
72. Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376-81
73. Yoshimura N, Nakai I, Ohmori Y, et al. Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients. Am J Kidney Dis 1988; 12: 11-7
74. Nakai I, Omori Y, Aikawa I, et al. Effect of cyclosporine on glucose metabolism in kidney transplant patients. Transplant Proc 1988; 20: 969-78
75. Sumrani NB, Delaney V, Ding Z, et al. Diabetes mellitus after renal transplantation in the cyclosporine era - an analysis of risk factors. Transplantation 1991; 51: 343-7
76. Vesco L, Busson M, Bedrossian J, et al. Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. Transplantation 1996; 61: 1475-8
77. Scantlebury V, Shapiro R, Fung J, et al. New Onset of diabetes in FK506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 1991; 23: 3169-70
78. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995; 59: 485-90
79. Vincenti F, Laskow DA, Neylan JF, et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. Transplantation 1996; 61: 1576-81
80. Woodle ES, Thistlethwaite JR, Gordon JH, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. Transplantation 1996; 62: 594-9
81. US multicenter FK506 liver study group. Use of Prograf (FK506) as rescue therapy for refractory rejection after liver transplantation. Transplant Proc 1993; 25: 679-88
82. Alessiani M, Cillo U, Fung JJ, et al. Adverse effects of FK506 overdosage after liver transplantation. Transplant Proc 1993; 25: 628-34
83. Armitage JM, Kormos RL, Fung J, et al. The clinical trial of FK506 as a primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 1991; 23: 3054-7
84. Sollinger for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-32
85. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for the prevention of acute rejection. Lancet 1995; 345: 1321-5
86. Laskow DA, Deierhoi MH, Hudson SL, et al. The incidence of subsequent acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS 61443). Transplantation 1994; 57: 640-3
87. Gores P, Najarian JS, Stephanian E, et al. Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Lancet 1993; 341: 19-21
88. Jindal RM, Popescu I, Emre S, et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. Transplantation 1994; 57: 1396-8
89. Fabrega AJ, Mesler P, Cohan J, et al. Long-term (24 month) follow-up of steroid withdrawal in renal allograft recipients with posttransplant diabetes mellitus. Transplantation 1995; 60: 1612-4
90. McDiarmid SV, Farmer DA, Goldstein LI, et al. A randomized prospective trial of steroid withdrawal after liver transplantation. Transplantation 1995; 60: 1443-50
91. Miller LW, Wolford T, McBride LR, et al. Successful withdrawal of corticosteroids in heart transplantation. J Heart Lung Transplant 1992; 11: 431-4
92. Sinclair NRS, for the Canadian Multicenter Transplant Study Group. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with a well-functioning graft. Can Med Assoc J 1992; 147: 645-57
93. Reisman L, Lieberman KV, Burrows L, et al. Follow-up of cyclosporine-treated pediatric renal allograft recipients after cessation of prednisone. Transplantation 1990; 49: 76-80
94. Hricik DE, Almawi WY, Strom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation 1994; 57: 979-89
95. Ratcliffe PJ, Dudley CRK, Higgins RM, et al. Randomized controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348: 643-8
96. Cantarovich D, Dantal J, Murat A, et al. Normal glucose metabolism and insulin secretion in CyA-treated nondiabetic renal allograft patients not receiving steroids. Transplant Proc 1990; 22: 643-4
97. Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991; 51: 374-7
98. Jordan ML, Shapiro R, Vivas CA, et al. FK506 'rescue' for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994; 57: 860-5
99. Ramos HC, Reyes J, Abu-Elmagd K, et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995; 59: 212-7
100. Thomson AW, Lu L, Murase N, et al. Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells 1995; 13: 622-39
101. European FK506 multicenter liver study group. Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-8
102. The US multicenter FK506 liver study group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-5
103. Fung J, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK506 vs cyclosporine. Transplant Proc 1991; 23: 2977-83
104. Mieles L, Gordon RD, Mintz D, et al. Glycemia and insulin need following FK506 rescue therapy in liver transplant recipients. Transplant Proc 1991; 23: 949-53
105. Krentz AJ, Dousset B, Mayer D, et al. Metabolic effects of cyclosporine A and FK506 in liver transplant recipients. Diabetes 1993; 42: 1753-9
106. Mor E, Sheiner PA, Schwartz ME, et al. Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. Transplantation 1994; 58: 380-2
107. Kai N, Motojima K, Tsunoda T, et al. Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. Transplantation 1993; 55: 936-40
108. Murase N, Lieberman I, Nalesnik MA, et al. Effect of FK506 on spontaneous diabetes in BB rats. Diabetes 1990; 39: 1584-6
109. Hariharan S, Munda R, Cavallo T, et al. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. Transplantation 1996; 61: 1161-5
110. Bartlett ST, Schweitzer E, Johnson LB, et al. Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation: a prospective trial of tacrolimus immunosuppression with percutaneous biopsy. Ann Surg 1996; 224: 440-52
111. Gruessner RWG, Burke GW, Stratta R, et al. A multicenter analysis of the first experience with FK506 for the induction and rescue therapy after pancreas transplantation. Transplantation 1996; 61: 261-73
112. Jindal RM, Sahota A. The role of cell migration and microchimerism in the induction of tolerance after solid organ transplantation. Postgrad Med J. In press
113. Starzl TE, Demetris AJ, Trucco M, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993; 17: 1127-52
114. Onwubalili JK, Obineche EN. High incidence of post-transplant diabetes mellitus in a single-center study. Nephrol Dial Transplant 1992; 7: 346-9
115. Rao M, Jacob CK, Shastry JCM. Post-transplant diabetes mellitus-a retrospective study. Nephrol Dial Transplant 1992; 7: 1039-42
116. Dumler F, Hayashi H, Hunter J, et al. Racial differences in the incidence of steroid diabetes in renal transplant patients. Henry Ford Hosp Med J 1982; 30: 14-6
117. Tornatore KM, Reed K, Venuto RC. Racial differences in the pharmacokinetics of methylprednisolone in black and white transplant recipients. Pharmacokinetics 1993; 13: 481-6
118. Tornatore KM, Biocevich DM, Reed KA, et al. Post-transplant diabetes mellitus and methylprednisolone pharmacokinetics in African-American and Caucasian renal transplant recipients. Clin Transplant 1995; 9: 289-96
119. Isoniemi HM, Ahonen J, Tikkanen MJ, et al. Long term consequences of different immunosuppressive regimens for renal allografts. Transplantation 1993; 55: 494-9
120. Kaisiske BL, Neylan JF, Riggio RR, et al. The effects of race on access and outcome in transplantation. N Engl J Med 1991; 324: 302-7
121. Butkus DE, Meydrech EF, Raju SS. Racial differences in the survival of cadaveric renal allografts; overriding effects of HLA matching and socioeconomic factors. N Engl J Med 1992; 327: 840-5
122. Ahn KJ, Kim YS, Lee HC, et al. Clinical characteristics and possible risk factors in postrenal transplant diabetes mellitus. Transplant Proc 1992; 24: 1581-2
123. Stegall MD, Everson GT, Schroter G, et al. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology 1997; 25: 173-7
124. Canzanello VJ, Schwartz L, Taler SJ, et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and Tacrolimus (FK506). Liver Transplant Surg 1997; 3: 1-9
125. Feinstein EI, Wannr C, Bohler J, et al. Endocrine and metabolic disorders following kidney transplantation. Am J Nephrol 1992; 12: 363-8
126. Hricik DE, Schulak JA. Metabolic effects of steroid withdrawal in adult renal transplant recipients. Kidney Int 1993; 44 Suppl. 43: 26-9